Special Issue

Antimicrobial Resistance and Drug Design—a Themed Issue in Honor of Professor Kim Lewis

Message from the Guest Editor

This Special Issue will honor Prof. Kim Lewis for his outstanding contributions in the fields of bacterial physiology, antibiotic discovery, and mechanisms of antibiotic resistance. Dr. Lewis is the University Distinguished Professor and the Director of the Antimicrobial Discovery Center at the Northeastern University in Boston, MA, Dr. Lewis is also a Fellow of the American Society for Microbiology and the American Association for the Advancement of Science (AAAS). and a member of the Faculty 1000 Pharmacology & Drug Discovery section, Dr. Lewis's current research interest, in his own words, is in the "mining of natural" antimicrobiome to discover a perfect antibiotic, if it exists". He has published more than 270 scientific papers with 46000+ citations. Dr. Lewis's work is recognized by multiple awards, and he was recently selected as the 2023 ASM recipient of the Applied Biology and Biotechnology Research Award. He continues to push the frontier of bacteriology and because of his extraordinary efforts "where the frontier" of science once was, is now the centre" (Georg Christoph Lichtenberg).

Guest Editor

Prof. Dr. Helen I. Zgurskaya

Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA

Deadline for manuscript submissions

closed (29 February 2024)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/142716

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

